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Abstract
Objective—Substantial evidence implicates interstitial collagenases of the MMP family in
plaque rupture and fatal thrombosis. Understanding the compensatory mechanisms that may
influence the expression of these enzymes and their functions therefore have important clinical
implications. This study assessed in mice the unknown relative impact of the two principal
collagenases on collagen content and other plaque characteristics.
Approach and Results—apoE−/− mice, MMP-13−/− apoE−/−, MMP-8−/− apoE−/− double
knockout (DKO) mice, and MMP-13−/− MMP-8−/− apoE−/− triple knockout (TKO) mice
consumed a high-cholesterol diet for 10 and 24 weeks. Both DKO and TKO mice showed
comparable atherosclerotic lesion formation compared to apoE−/− controls. Analysis of aortic root
sections indicated that lesions of MMP-8/MMP-13-deficient and MMP-13-deficient mice
accumulate more fibrillar collagen than apoE−/− controls and MMP-8−/− apoE−/− DKO. We
further tested the relative impact of MMPs on plaque collagenolysis using in situ zymography.
MMP-13 deletion alone abrogated collagenolytic activity in lesions, indicating a predominant role
for MMP-13 in this process. MMP-13 and MMP-13/MMP-8 deficiency did not alter macrophage
content, but associated with reduced accumulation of smooth-muscle cells.
Conclusions—These results show that among MMP interstitial collagenases in mice, MMP-13
prevails over MMP-8 in collagen degradation in atheromata. These findings provide a rationale for
the identification and selective targeting a predominant collagenase for modulating key aspects of
plaque structure considered critical in clinical complications, although they do not translate
directly to human lesions, which also contain MMP-1.
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INTRODUCTION
Atherosclerosis remains the major cause of death and premature disability worldwide1.
Rupture of plaques with a thin fibrous cap causes most fatal myocardial infarctions2, 3.
Because interstitial collagen confers tensile strength upon the fibrous cap, collagenolysis in
atheromata participates critically in plaque disruption. Previous work has implicated
interstitial collagenases of the matrix metalloproteinase (MMP) family in the regulation of
aspects of the structure of atherosclerotic plaques that associate with rupture and fatal
thrombosis in humans4–7. These data collectively suggest that therapeutic targeting of
interstitial collagenases might reduce characteristics of plaques associated with rupture, and
thus limit thrombotic complications.
Yet, broad spectrum inhibitors of MMPs cause unwanted effects that preclude their clinical
use,8–11 and pilot clinical studies failed to show beneficial effects of MMP inhibitors8 due to
lack of specificity. Understanding the potential redundancy of these enzymes in the
regulation of plaque collagen content therefore has not only mechanistic interest, but also
important implications for the design of targeted strategies for reducing complications of
atherosclerosis. In particular, our prior work showed that mice bearing a mutant form of
interstitial collagen that resists breakdown by MMPs accumulate plaque collagen12.
Subsequent studies showed that selective inhibition of MMP-13 can also increase the
content of plaque collagen6, 13. In addition, these studies presented evidence that MMP-13
predominates as an interstitial collagenase in mouse atheromata. Yet, to date no data directly
compare the contribution of combined deficiency of MMP-13 and the other principal
interstitial collagenase in mouse lesions, MMP-8, on collagen accumulation and other
aspects of plaque structure and cellular composition.4, 14
Mouse atherosclerotic plaques contain two principal interstitial collagenases, whereas
human lesions contain three MMPs of this class5, 15. Therefore, the mouse offers a defined
approach for testing the redundancy of interstitial collagenase actions during atherogenesis.
The present study tested the novel hypothesis that loss of MMP-13 function alone achieves a
similar increase in collagen content in experimental atheromata as that caused by deficiency
of both MMP-13 and MMP-8. Our study examined both early and established atheromata to
assess the role of collagenases in both formation and progression of lesions. The findings
furnish new mechanistic insight into the biological roles of interstitial collagenases in
experimental atherosclerosis, and support the selective targeting of a single collagenase to
influence decisively aspects of plaque structure deemed critical in clinical complications.
MATERIAL AND METHODS
Materials and Methods are available in the online-only Data Supplement.
RESULTS
Characteristics of mice
To examine the relative contribution of MMP-8 and MMP-13 to atherosclerosis,
apoE−/−mice, MMP-13−/− apoE−/−, MMP-8−/− apoE−/− double knockout (DKO) mice, and
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MMP-13−/− MMP-8−/− apoE−/− triple knockout (TKO) mice consumed an atherogenic diet,
either for 10 weeks to provoke early lesions (n≥12 per group) or for 24 weeks for advanced
atheromata (n≥15). Total cholesterol, and triglycerides did not differ between apoE−/− and
MMPs mutant mice after 10 weeks of the atherogenic diet (Table 1). TKO mice, however,
had higher body weight (**p≤0.01) than apoE−/− and DKOs mice (**p≤0.01) at this time
point. After 24 weeks, TKO mice consistently exhibited increased body weight compared
with DKO mice, with higher plasma cholesterol levels compared to controls (**p≤0.01).
Lack of MMP-8 and MMP-13 activity does not affect the development of atherosclerosis in
apoE-deficient mice
Oil red O en face staining determined the lipid content of atherosclerotic lesions in the
descending aorta. Overall, TKO mice exhibited similar plaque size after 10 and 24 weeks on
an atherogenic diet, compared with apoE−/− mice and DKO animals (Figures 1A–C). In the
aortic root and the brachiocephalic artery, where plaques form earlier, histological analysis
of plaque size showed a similar result. Genetic inactivation or pharmacologic inhibition of
MMP-13 associated with comparable extent of atheromata compared to apoE-deficient
controls (Figures 1D and 1E), in accord with the results observed in our previous
studies.6, 13 MMP-8 deletion combined with a lack of MMP-13 had no significant additional
effect regarding plaque size, suggesting that MMP-8 and MMP-13 play a minor role in
plaque lipid accumulation.
MMP-13 deficiency yields increased more intraplaque collagen accumulation compared to
MMP-8-deficient mice
We further investigated collagen content by analyzing aortic root sections stained by
picrosirius red under polarized light. After 10 weeks on an atherogenic diet (Figure 2A), the
intima of aortic lesions from MMP-13−/− apoE−/− mice accumulated more interstitial
collagen than apoE−/− mice, affirming the critical role of MMP-13 in plaque collagenolysis.
MMP-8−/− apoE−/− exhibited a slight and statistically insignificant increase in plaque
collagen. MMP-13 deletion associated with a 71% increase in collagen accumulation
compared to MMP-8 deficient mice, indicating a predominant role of MMP-13 in collagen
degradation in murine atheromata. Combined deletion of MMP-8 and MMP-13 in TKO
mice did not correlate with any significant additional increase of collagen accumulation
compared with DKO mice, further suggesting that MMP-8 contributes little to this process
(Figure 2B). Established plaques (Figure 2C), showed a 66.2% increase in the fibrillar
collagen content in MMP-13 apoE DKO mice compared to apoE−/− controls (Figure 2D).
Strikingly, lesions from TKO mice showed less collagen accumulation compared to those
from DKO mice, and did not differ significantly from apoE−/− controls or MMP-8 apoE
deficient animals. Analysis of picrosirius red-stained collagen fibers under filtered polarized
light allowed us to assess the impact of MMP-13 and MMP-8 on this index of collagen fiber
thickness.16–18 This approach revealed an increased proportion of mature, thick collagen
fibers in DKO mice (observed under polarized light with a red filter) in early and advanced
atherosclerotic lesions, compared with apoE-deficient mice. When associated with MMP-13
deficiency, lack of MMP-8 did not enrich early or advanced atherosclerotic lesions with
thick collagen fibrils.
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MMP-13 deletion alone abrogates collagenolysis in atherosclerotic lesions
To estimate further the relative contribution of MMP-13 and MMP-8 on collagenolysis in
lesions, we performed in situ zymography in the aortic roots of mice after 24 weeks of
atherogenic diet. For each group, we compared the mean fluorescence intensity derived from
a cleavable collagen-based probe in the presence or absence of a broad-spectrum
metalloproteinase inhibitor (ilomastat) as a control (Figure 3). MMP-13 deletion alone in
DKO mice completely inhibited collagen degradation in lesions, as did ilomastat treatment
(Figure 3A). MMP-8 deficiency did not significantly reduce collagenase activity compared
to apoE−/− control. MMP-13 apoE DKO and TKO mice exhibited similar collagenase
activity, indicating that compensatory changes in MMP-8 activity do not contribute to
plaque collagenolytic capacity in mice with congenital absence of MMP-13 (Figures 3B and
3C).
MMP-13 drives the reduction of SMC accumulation on atheromata
SMCs produce most of the interstitial collagen in atherosclerotic lesions. We assessed
whether increased collagen content also could result in part from an increase in SMCs in
atheromata in the absence of MMP collagenases. Histological analysis showed that SMC
accumulation decreased in both MMP-13 apoE DKO and TKO mice, compared with
MMP-8−/− apoE−/− animals, which did not show significant difference with the apoE−/−
controls. There was a non-significant trend for the early lesions of TKO mice to have fewer
SMC (Figure 4B), as previously reported by Fukumoto et al. in atheromata of mice with
genetically induced collagenase resistance. In established lesions in mice with MMP-13 or
with combined MMP-8/MMP-13 deficiencies SMC content declined significantly (Figure
4C).19 DKO and TKO mice had similar SMC content. The number of SMCs per mm2 of
plaque did not vary significantly, but still indicated the trend of the decrease in SMC content
in collagenase mutant mice (Figure 4D–E). The ratio between intimal collagen accumulation
and SMC number was higher within the DKO mice (2.6 fold compared to apoE−/−) and
TKO mice (1.6 fold compared to apoE−/−) in established atheromata (Figure 4F–G).
Previous studies reported that MMP-13 collagenase does not impact the de novo collagen
expression in lesions.6 Taken together, these results suggest that increased collagen content
in MMP-deficient mice results from inhibition of collagen degradation, and not from
increased production by intimal cells.
Neither MMP-8 nor MMP-13 influences macrophage accumulation
Because macrophages constitute a major source of matrix-degrading proteinases,
particularly interstitial collagenases within human atheromata,5 we investigated their
presence in atheromatous lesions lacking MMP-8 and/or MMP-13. Macrophage
accumulation did not differ between the intima of aortic roots lacking MMP-13, MMP-8, or
lacking both MMP-8 and MMP-13, after 10 and 24 weeks on an atherogenic diet (Figures
5A and 5B). These results indicate that MMP collagenases, while affecting SMC
accumulation in advanced plaques, do not impede recruitment of inflammatory cells.
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Lack of MMP-13 and MMP-8 reduces features associated with plaque rupture
We further assessed features associated with plaque disruption in histological sections of
lesions in brachiocephalic arteries, a site of lesions considered prone to rupture in
atherosclerotic mice.20 We measured the size of the necrotic core area in the plaques and
showed that lack of both MMP-8 and MMP-13 associated with a significant decrease in
necrotic core size (Figure 5C–D).
DISCUSSION
Degradation of the extracellular matrix in the plaque’s fibrous cap likely renders a lesion
more prone to rupture in humans. Previous data from our group and others suggest that
regulation of collagenolysis by MMP collagenases, in conjunction with reduced interstitial
collagen synthesis by SMCs in inflamed atheromata generate so called "vulnerable"
lesions.12, 21 These studies have not only provided novel mechanistic insight into
pathogenesis, but have identified MMPs as an appealing target for clinical intervention to
prevent the thrombotic complications of atherosclerosis. Three members of the MMP
family, denoted interstitial collagenases (MMP-1, MMP-8, and MMP-13), can cleave triple-
helical fibrillar collagen and associate with inflamed plaques in humans.4, 5 These enzymes
catalyze the critical initial step in collagen catabolism, yielding fragments that can be
degraded by other collagenases or MMPs.22 Initial attempts to inhibit MMPs in clinical
trials have consistently failed, due to lack of selectivity of the agents used and associated
unwanted actions. In atherosclerosis, therefore, identifying which MMP collagenase(s) plays
a major role in this process, and assessing whether lack of function of one interstitial
collagenase leads to compensatory changes in other family members has both mechanistic
and therapeutic interest.
We previously demonstrated that MMP-13 regulates collagen accumulation in vivo in
murine atheromata.6, 13 Mice express another interstitial collagenase, MMP-8, an enzyme
also found in human plaques.4 In addition, high serum levels of MMP-8 associate with
adverse cardiovascular outcomes.23 Laxton et al. reported that inactivating MMP-8 reduced
the extent of atherosclerosis in apoE−/− mice, and increased collagen content in developing
atheromata (12 weeks on atherogenic diet).14
In accord with our prior studies, the present results demonstrate that MMP-13 controls the
collagen content of both early and established plaques in mice. This study addressed the
crucial unresolved issue of the relative contribution of MMP-8 and -13 to these critical
aspects of plaques. Concomitant lack of MMP-8 and MMP-13 did not augment collagen
accumulation to a greater extent than MMP-13 deficiency alone.
This result indicates a lack of mechanisms that compensate deficiency of MMP-8 or
MMP-13 in regard to collagen metabolism in plaques, in contrast to the situation we
observed in mouse myocardium with impaired collagenolysis.24 Our in situ zymographic
data furnish strong evidence that MMP-13 predominates over MMP-8 as an interstitial
collagenase in mouse atheromata. Although MMP-8 shares collagenolytic activity with
MMP-13, it does not add to the action of MMP-13 on plaque collagenolysis. This novel
finding supports our previous studies, in which genetically- or pharmacologically-driven
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selective inhibition of MMP-13 did not affect the expression of other potentially
collagenolytic enzymes, such as MMP-8, MMP-14, MMP-12, or cathepsin K, in lesions.6, 13
While we can't exclude that MMP-8 plays a role in plaque biology, as shown by Laxton et
al14, the present study did not recapitulate the results obtained previously. The present study
did not recapitulate the results obtained previously. This discrepancy could result from
differences in time points studied or other experimental variations.
The present study also demonstrates a broader impact of MMP collagenases on
atherosclerosis biology. Our results show that MMP-13, or MMP-13/MMP-8 deficiency
associate with reduced lesional SMCs, even if it does not alter plaque size significantly.
Increased intimal collagen content and lack of collagenolytic capacity could impede SMC
migration within the plaque, as reflected by the reduced number of intimal SMCs observed
in DKO and TKO mice. This situation resembles that we previously observed in
collagenase-resistant mice that harbor a mutation in the substrate rather than the proteases.19
Beyond their roles in extracellular matrix remodeling, MMPs could cleave other substrates.
The differences in the lipid profile and body weight in the TKO observed here indicate that
such non-canonical substrates might include factors that regulate metabolism. This
possibility provides a potentially fruitful field for further investigation, beyond the scope of
the present study that focused on effects of interstitial collagenases on the extracellular
matrix.
MMP-13 and MMP-8 can cleave various membrane-associated and extracellular proteins, in
addition to collagen fibers, that could account for the reduced plaque progression in KO
mice. MMP-8 plays a more important role in the cleavage of important molecular mediators,
such as macrophage inflammatory protein-1 alpha (MIP-1α), CXCL-9, CXCL-10 or
angiotensin I.25–29 Indeed, previously reported results showing decreased atherosclerosis in
MMP-8−/− apoE−/− mice most likely relate to the modulation of angiotensin production and
its impact on blood pressure and vascular inflammation.14 MMP-13 can also affect
inflammatory processes by cleaving chemokines (MCP-1, MCP-2) and adhesion molecules
(ICAM-1).27, 30 While the effect of MMP-13 and MMP-8 on plaque development reported
in this study could result in part from regulation of various inflammatory mediators, the
similar macrophage content in mice lacking MMP collagenases suggests that MMP-8 and
MMP-13 activities do not alter the recruitment, proliferation, and/or apoptosis of
inflammatory cells.
This work probed the mechanism of the regulation of collagen structure in atherosclerotic
plaques, and did not aim to model the human disease. As mice do not express MMP-1, a
collagenase expressed in human plaques, the results do not translate directly to human
disease. Although MMP-1 colocalizes with MMP-13 in the shoulder regions of inflamed
human atheromatous plaques and that specific MMP-1 haplotypes associate with plaque
burden, its direct role in atherosclerosis remains unclear.7, 31–33 Macrophage-specific
transgenic mice expressing human MMP-1 had less advanced atherosclerosis, but
overexpression of human tissue inhibitor of metalloproteinase-1 (TIMP-1, an inhibitor of
collagenases and other MMPs) showed a tendency to reduce atherosclerotic lesions in
apoE−/− mice.34
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Beyond the novel mechanistic insight into the redundancy and roles of collagenases in the
context of atherosclerosis, these results have therapeutic implications. Broad spectrum MMP
inhibition has proven intolerable in clinical studies. Our present findings indicate that
selective inhibition of a single member of the MMP interstitial collagenase family can alter
fundamental aspects of plaques limiting potential unwanted actions of indiscriminate MMP
inhibition. The weight gain in the MMP-13/MMP-8 mice observed here provides an
example of an unpredicted and unwanted consequence of broader interference with MMP
function. Thus, this study provides new insights on the respective importance of MMP
collagenases in murine atheromata. Identification of the predominant MMP collagenase in
human lesions could therefore lead to the basis for modulating key aspects of plaque
structure considered critical in clinical complications.
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SIGNIFICANCE
Atherosclerosis remains the major cause of death and premature disability worldwide.
Rupture of plaques with a thin fibrous cap causes most fatal myocardial infarctions.
Substantial evidence implicates interstitial collagenases of the MMP family in plaque
rupture and fatal thrombosis by degrading the collagen that confers the tensile strength
upon the fibrous cap. Our study shows in vivo that among MMP interstitial collagenases,
MMP-13 predominates over MMP-8 in collagen degradation in murine atheromata.
Because broad spectrum inhibition of MMPs is not translatable into the clinic, due to
detrimental side effects, our findings provide the proof of concept that MMP
collagenases have differential impact on collagenolysis in atherosclerotic plaques, and
that selective targeting of single collagenase could modulate key aspects of plaque
structure.
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Figure 1.
Oil-red-O staining of lesions in abdominal aortas from mice after 10 and 24 weeks on an
atherogenic diet (A). Quantification of positive areas after 10 weeks (B) and 24 weeks (C)
on western diet. Histological analysis of plaque size on aortic root (D) and brachiocephalic
artery sections. Bars represent mean ± SEM. (*p<0.05).
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Figure 2.
Picrosirius red staining viewed under linearly polarized light to show fibrillar collagen in
plaques after 10 (A) and 24 (C) weeks of atherogenic diet. Quantification of intimal collagen
content (B–D). Bars represent mean ± SEM. (*p<0.05, **p<0.01, ***p<0.001).
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Figure 3.
In situ zymography for collagenolytic activity in mouse arteries. Representative sections of
aortic roots of mutant mice after 24 weeks of atherogenic diet incubated with a fluorescent
collagenase-activatable probe in presence or in absence of the broad MMP inhibitor
ilomastat (A). Quantification of the mean fluorescence in the intima (B) and the mean
fluorescence ratio compared to ilomastat treated samples (C) are represented (n=5). Bars
represent mean ± SEM (*p<0.05, **p<0.01, ***p<0.001).
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Figure 4.
Representative alpha-smooth mucle cell (SMC) actin staining of aortic root sections of KO
mice after 10 and 24 weeks on atherogenic diet (A). Quantification of smooth muscle cells
number per lesion and per lesion area after 10 weeks (B,D) and 24 weeks of atherogenic diet
(C,E). Intimal collagen content normalized by the number of SMCs in early (F) and
advanced lesions (G). Bars represent mean ± SEM. (n≥10 per group, *p<0.05, **p<0.01,
***p<0.001).
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Figure 5.
Representative micrographs (A) and quantification of macrophage (Mac 3) in intima of
developing and advanced lesions (B). Bars represent mean ± SEM. Representative sections
of brachiocephalic arteries of mutant mice after 24 weeks of atherogenic diet (C).
Quantification of necrotic core area (acellular areas within the lesions) (D). Bars represent
mean ± SEM. (n≥10 per group, *p<0.05).
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